Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early and late-stage drug development, explains Hallorans Carolina Ahrendt.

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The companys lead program is an exenatide implant.